Fri, May 9, 11:01 AM (9 days ago)
**KIORA PHARMACEUTICALS, INC. (KPRX) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 (Q1 2024: $16,000,000) - **Net Loss:** $2,192,980 (Q1 2024: Net Income $13,453,207) - **Operating Expenses:** $2,330,354 (Q1 2024: $2,777,906) - **Cash & Short-Term Investments:** $24,075,835 (Q1 2024: $34,792,082) - **Accumulated Deficit:** $145,575,102 (Q1 2024: $143,382,122) **Key Metrics:** - **Gross Margin:** Not applicable (no revenue) - **Operating Margin:** -100% (Q1 2024: 489%) - **Net Margin:** -100% (Q1 2024: 840%) **Cash Flow:** - **Operating Cash Flow:** -$2,704,199 (Q1 2024: $13,624,855) - **Investing Cash Flow:** $2,672,782 (Q1 2024: $0) - **Financing Cash Flow:** $0 (Q1 2024: $15,247,632) **Earnings Changes:** - **Quarter-over-Quarter:** Net loss of $2,192,980 vs. net income of $13,453,207 - **Year-over-Year:** Significant decrease in revenue and net income **Trends & Uncertainties:** - **Positive Trends:** Successful clinical trials for KIO-301 and KIO-104. - **Uncertainties:** Need for additional financing, regulatory approvals, and market acceptance. **Future Operations Impact:** - **Planned Operations:** Funded into late 2027. - **Future Financing:** Equity, debt, collaborations, grants. - **Potential Risks:** Failure to raise capital, regulatory setbacks, market competition. **Key Takeaways:** - Kiora Pharmaceuticals reported a net loss of $2,192,980 for Q1 2025, compared to a net income of $13,453,207 in Q1 2024. - The company has sufficient cash to fund operations into late 2027 but will need additional financing for future growth. - Kiora is focused on developing and commercializing ophthalmic therapies, with promising clinical trial results for KIO-301 and KIO-104.